<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%20%5BNLMID%5D&amp;fc = none&amp;v=2.18.0.post9+E46 2414＆utm_campaign =期刊＆utm_source = chrome＆ff = 20250403141505＆utm_medium = rss＆utm_content = 101560960<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;fc=None&amp;v=2.18.0.post9+e462414&amp;utm_campaign=journals&amp;utm_source=Chrome&amp;ff=20250403141505&amp;utm_medium=rss&amp;utm_content=101560960" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> THU，2025年4月3日18:15:06 +0000</lastbuilddate><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> &lt;em>; cxcr2p1 &lt;/em>;通过增加肿瘤的免疫浸润，增强了胃癌对PD-1抑制剂的反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176817/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>结论：CXCR2P1的高表达与对PD-1抑制剂的更好反应相关。它通过增加免疫浸润并改变免疫细胞的比例来重塑免疫微环境。在肿瘤免疫微环境中，CXCR2P1可以促进炎症，增强抗原表现并激活PD-1/PD-L1相关信号通路，这可能是通过CXCR2P1-MIR215轴来实现的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1545605。 doi：10.3389/fimmu.2025.1545605。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：近年来，免疫疗法已成为癌症治疗中的关键方法。但是，胃癌对免疫疗法的反应表现出明显的异质性。因此，可能会从免疫疗法中受益并发现新型治疗靶点的胃癌患者的早期鉴定至关重要。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">材料和方法：我们从欧洲核苷酸档案（ENA）和基因表达综合（GEO）数据库中收集了数据。在PRJEB25780项目中，我们进行了WGCNA分析和LASSO回归，并选择了<i>CXCR2P1</i>进行后续分析。然后，我们比较了不同组之间<i>CXCR2P1</i>的表达差异。 Kaplan-Meier曲线用于分析<i>CXCR2P1</i>的预后价值，该曲线通过Project Imvigor210和Geo数据集验证。估计值和Cibersort算法用于评估<i>CXCR2P1</i>对肿瘤免疫微环境的重塑作用。差异表达的基因（DEG）分析，富集分析，基因集富集分析（GSEA）和共表达分析用于探索<i>CXCR2P1涉及的细胞生物学功能和信号通路。</i> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：WGCNA将<i>CXCR2P1</i>识别为与对胃癌PD-1抑制剂的免疫反应显着相关的中心基因。响应者的<i>CXCR2P1</i>表达升高，并与更好的预后相关。功能分析揭示了其通过促进包括M1巨噬细胞，活化的<i>CD4</i> + T细胞和滤泡辅助T细胞在内的免疫细胞浸润来重塑肿瘤免疫微环境中的作用。 <i>CXCR2P1</i>通过MHC-II复合物增强了抗原表现，影响了关键的免疫途径，例如Toll样受体信号传导和T细胞激活，这导致了PD-L1表达的上调。 GSEA显示<i>CXCR2P1</i>与microRNA相关。通过DEG分析和表达分析， <i>MIR215</i>被确定为<i>CXCR2P1</i>的潜在直接靶标。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：CXCR2P1的高表达与对PD-1抑制剂的更好反应相关。它通过增加免疫浸润并改变免疫细胞的比例来重塑免疫微环境。在肿瘤免疫微环境中， <i>CXCR2P1</i>可以促进炎症，增强抗原表现并激活PD-1/PD-L1相关的信号通路，这可以通过<i>CXCR2P1</i> - <i>MIR215</i> AXIS来实现。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176817/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176817</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961440/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961440</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1545605>10.3389/fimmu.2025.1545605</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176817</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Xinchun Wu</dc:creator><dc:creator>森·侯</dc:creator><dc:creator>yingjiang ye</dc:creator><dc:creator> Zhidong Gao</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>&lt;em>; cxcr2p1 &lt;/em>;通过增加肿瘤的免疫浸润，增强了胃癌对PD-1抑制剂的反应</dc:title><dc:identifier>PMID：40176817</dc:identifier><dc:identifier> PMC：PMC11961440</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1545605</dc:identifier></item><item><title>评估双重病原体识别受体激动剂作为呼吸综合病毒 - 病毒样颗粒的辅助因子，用于肺部递送</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176816/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>简介：呼吸道合胞病毒（RSV）仍然是全球健康问题，特别是对于发展中国家的婴儿和幼儿。尽管进行了持续的研究工作，但有效的RSV疫苗尚未得到广泛使用。在疫苗制剂中，使用两个单独的模式识别受体（PRR）激动剂作为佐剂已显示可增强针对抗原的免疫反应。使用两个佐剂的限制是他们不需要... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月17日； 16：1561297。 doi：10.3389/fimmu.2025.1561297。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：呼吸道合胞病毒（RSV）仍然是全球健康问题，特别是对于发展中国家的婴儿和幼儿。尽管进行了持续的研究工作，但有效的RSV疫苗尚未得到广泛使用。在疫苗制剂中，使用两个单独的模式识别受体（PRR）激动剂作为佐剂已显示可增强针对抗原的免疫反应。使用两个佐剂的限制是，它们不一定必须与同一细胞上的PRR结合。这项研究评估了两种不同的双PRR结合嵌合分子CL413（TLR2/TLR7激动剂）和Cl429（TLR2/NOD2激动剂）作为RSV病毒样颗粒（VLP）（VLP）的辅助因素（VLP）的疗效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：单独使用RSV-VLP或与CL413，CL429佐剂进行两次免疫的BALB/C小鼠，单个PRR激动剂PAM3CSK4+ L18-MDP或PAM3CSK4+ imiquimod通过肺途径。单个PRR激动剂佐剂的混合物用作嵌合佐剂的对照。通过测量血清和呼吸道中的抗体水平来评估免疫反应；肺和脾脏中的细胞因子，B和T细胞反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：用CL413辅助VLP的肺免疫对RSV F和G蛋白诱导了稳健的鼻IgA反应，对于其他辅助组合而言未观察到这一点。 CL413还提高了血清IgG水平并促进了平衡的Th1/Th2响应，这是IgG2A/IgG1比例所证明的。 CL413引起了小鼠肺中强烈的促炎反应，包括IFN-γ，TNF-α，IL-6和IL-17A的水平升高。流式细胞仪分析表明，在小鼠肺中，组织居民居民居民居民的B细胞数量增加，这些B细胞用CL413和CL429辅助的VLP辅助。在接收嵌合分子辅助的VLP的小鼠的肺和脾脏中，CD4+和CD8+ T细胞的反应也得到了增强。用福尔马林灭活的RSV（FI-RSV）免疫的小鼠被用作RSV挑战后疫苗诱导病理的阳性对照，发生了肺泡炎，血管周围浸润。在RSV挑战后，所有接收辅助VLP配方的小鼠均显示针对肺病理的保护。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：缺乏病理，再加上强大的粘膜和全身免疫反应，表明辅助RSV-VLP的肺部递送可能会提供有效的保护，而无需疫苗增强疾病的风险。该研究还表明，嵌合TLR2/TLR7激动剂CL413是RSV-VLPS诱导粘膜和全身免疫反应的有前途的辅助，并保证在更先进的临床前模型中进一步研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176816/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176816</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11962540/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11962540</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1561297>10.3389/fimmu.2025.1561297</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176816</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator>艾哈迈达利（Ahmedali）的Mandviwala</dc:creator><dc:creator> Komal Liman</dc:creator><dc:creator> Anke LW Huckriede</dc:creator><dc:creator> Vidya A Arankalle</dc:creator><dc:creator> Harshad P Patil</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>评估双重病原体识别受体激动剂作为呼吸综合病毒 - 病毒样颗粒的辅助因子，用于肺部递送</dc:title><dc:identifier>PMID：40176816</dc:identifier><dc:identifier> PMC：PMC11962540</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1561297</dc:identifier></item><item><title>一种可进行的免疫治疗水凝胶通过&lt;em>; in Initu &lt;/em>;激活晚期乳腺癌术后治疗的刺激途径增强T细胞免疫力</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176815/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>晚期乳腺癌的完全手术切除是高度挑战性的，并且经常留下微观肿瘤灶，导致不可避免的复发。免疫抑制性肿瘤微环境（TME）的术后形成可降低免疫疗法对残留肿瘤的疗效。尽管细胞毒性化学治疗剂具有通过免疫原性死亡（ICD）作用增强癌症免疫疗法的能力，但系统施用的化学药物通常无法获得残留的疗法... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1523436。 doi：10.3389/fimmu.2025.1523436。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">晚期乳腺癌的完全手术切除是高度挑战性的，并且经常留下微观肿瘤灶，导致不可避免的复发。免疫抑制性肿瘤微环境（TME）的术后形成可降低免疫疗法对残留肿瘤的疗效。尽管细胞毒性化学治疗剂具有通过免疫原性死亡（ICD）作用加强癌症免疫疗法的能力，但系统施用的化学剂通常无法访问残留的肿瘤部位，并且无法引起抗肿瘤免疫反应。本文中，我们提出了一种新型的可注射免疫治疗水凝胶（Sigel@sn38/aox40），该水凝胶带有触发DNA靶向化学疗法7-乙基-10-羟基环蛋白（SN38）和抗-OX40抗体抗体（AOX40）。 SN38和AOX40的持续位置释放激活了干扰素基因（STING）途径的刺激剂，I型I型干扰物的表达，协同促进树突状细胞（DC）激活，并启动持续的T细胞介导的T型床中的T型均与Tumor Recorence无处不在，从而消除了持久性的床中的免疫反应。总体而言，我们设计的Sigel@SN38/AOX40在乳腺癌切除后诱导了坚固而持久的肿瘤免疫力，并表现出巨大的临床翻译潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176815/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176815</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961417/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961417</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1523436>10.3389/fimmu.2025.1523436</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176815</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Baozhen Zhang</dc:creator><dc:creator> li</dc:creator><dc:creator> jihua ji</dc:creator><dc:creator> Xinghui si</dc:creator><dc:creator> xiaojiao yin</dc:creator><dc:creator> Guofeng ji</dc:creator><dc:creator> Liqun Ren</dc:creator><dc:creator> Haochen Yao</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>一种可进行的免疫治疗水凝胶通过&lt;em>; in Initu &lt;/em>;激活晚期乳腺癌术后治疗的刺激途径增强T细胞免疫力</dc:title><dc:identifier>PMID：40176815</dc:identifier><dc:identifier> PMC：PMC11961417</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1523436</dc:identifier></item><item><title>氧代谢异常和高空脑水肿</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176814/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>低估缺氧被广泛认为是高空脑水肿（HACE）的突出危险因素，这有助于加剧多种病理机制，包括氧化应激，线粒体功能障碍，干扰血液 - 脑屏障;脑屏障完整性，神经炎，神经衰弱，神经衰减和神经元素。在这些机制中，氧代谢的异常，包括缺氧，氧化应激和线粒体功能障碍，在...的病理生理学中起关键作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1555910。 doi：10.3389/fimmu.2025.1555910。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">低估缺氧被广泛认为是高空脑水肿（HACE）的突出危险因素，这有助于加剧多种病理机制，包括氧化应激，线粒体功能障碍，干扰血液 - 脑屏障;脑屏障完整性，神经炎，神经衰弱，神经衰减和神经元素。在这些机制中，氧代谢的异常，包括缺氧，氧化应激和线粒体功能障碍，在HACE的病理生理学中起关键作用。在这篇综述中，我们的目标是通过研究氧代谢的潜在参与来增强我们对与HACE有关的潜在分子机制的理解。解决氧代谢中的畸变有望提供创新的治疗策略来管理HACE。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176814/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176814</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961428/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961428</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1555910>10.3389/fimmu.2025.1555910</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176814</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> li</dc:creator><dc:creator>张张</dc:creator><dc:creator>小氧</dc:creator><dc:creator>Qiaoying Jin</dc:creator><dc:creator> Xingxing Zheng</dc:creator><dc:creator>李莫</dc:creator><dc:creator>Zejiao DA</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>氧代谢异常和高空脑水肿</dc:title><dc:identifier>PMID：40176814</dc:identifier><dc:identifier> PMC：PMC11961428</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1555910</dc:identifier></item><item><title>成功治疗与药物诱导的肝损伤的耐火系统性红斑狼疮相关的免疫血小板减少症与telitacicept：病例报告和审查</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176813/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>免疫血小板减少症（ITP）是全身性红斑狼疮（SLE）的常见临床表现。药物疗法包括糖皮质激素（GCS），疾病改良的抗风湿药（DMARD）和生物制剂。难治性血小板减少症可能是威胁生命的，使用有效药物在疾病改善中起着至关重要的作用。在这里，我们报告了SLE次要的ITP案例。地塞米松（DEX），环孢菌素A（CSA）和Hetrombopag的使用导致药物诱导的肝损伤。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1473190。 doi：10.3389/fimmu.2025.1473190。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">免疫血小板减少症（ITP）是全身性红斑狼疮（SLE）的常见临床表现。药物疗法包括糖皮质激素（GCS），疾病改良的抗风湿药（DMARD）和生物制剂。难治性血小板减少症可能是威胁生命的，使用有效药物在疾病改善中起着至关重要的作用。在这里，我们报告了SLE次要的ITP案例。地塞米松（DEX），环孢菌素A（CSA）和Hetrombopag的使用导致药物诱导的肝损伤。随后，选择了Telitacicept并成功控制了患者的病情。这表明Telitacicept可能是难治性SLE-ITP的新治疗选择。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176813/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176813</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961413/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961413</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1473190>10.3389/fimmu.2025.1473190</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176813</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Xuefei li</dc:creator><dc:creator> Yao fu</dc:creator><dc:creator> Haiqin Yin</dc:creator><dc:creator>朱尔朱</dc:creator><dc:date>2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>成功治疗与药物诱导的肝损伤的耐火系统性红斑狼疮相关的免疫血小板减少症与telitacicept：病例报告和审查</dc:title><dc:identifier>PMID：40176813</dc:identifier><dc:identifier> PMC：PMC11961413</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1473190</dc:identifier></item><item><title>脑损伤，内分泌干扰和与患有晚期HIV诊断男性发生性关系的HIV阳性男性的免疫失调</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176812/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>结论：这项研究表明，LD可能导致HIV阳性MSM中的脑损伤，内分泌破坏和免疫失调。因此，迫切需要制定针对晚期诊断的公共卫生策略，重点是加强对高风险人群的筛查和早期检测，以及监测LD患者的脑损伤，内分泌和免疫功能，并制定精确的，个性化的干预策略，以减少... ... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1436589。 doi：10.3389/fimmu.2025.1436589。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在公共卫生领域，晚期人类免疫缺陷病毒（HIV）诊断仍然很普遍，并且与神经精神不良事件有关。然而，关于晚期HIV诊断（LD）对与男性发生性关系的HIV阳性男性（MSM）的影响的有关HIV晚期诊断（LD）（LD）的影响的文件有限。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：参与者（38 ld和34个MSM的非LD）经历了全面的传染病和精神病评估，多模式磁共振成像（MRI）扫描，神经营养因素，内分泌和免疫学评估。免疫细胞水平以及神经营养因子和激素的周围血浆浓度分别使用酶连接的免疫吸附测定法和流式细胞仪测量。 T1加权图像以及静止状态功能MRI用于评估脑功能和结构，同时还检查了成像改变与临床以及外周血液变量之间的相关性。这项研究的数据源自与HIV相关的神经精神疾病研究中的一部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与非LLD组的参与者相比，LD组的参与者显示出较低的总灰质体积（GMV），而GMV的GMV降低了，主要在左上角回合中观察到。 LD组的参与者在某些区域表现出大脑功能的差异，并降低了这些变化区域和连接结构之间的功能连通性。对方差的双向阶乘分析研究了组与神经精神疾病之间的主要影响和相互作用，揭示了LD对特定大脑区域的重要主要影响。此外，我们发现LD组中的个体具有较高的皮质醇水平，中央记忆T细胞的频率较低，并且在双重阴性T细胞中的表达水平升高。这些成像发现与内分泌，免疫和临床变量显着相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，LD可能导致HIV阳性MSM中的脑损伤，内分泌破坏和免疫失调。因此，迫切需要制定针对晚期诊断的公共卫生策略，重点是加强对高风险人群的筛查和早期检测，以及监测LD患者的脑损伤，内分泌和免疫功能，并制定精确的，个性化的干预策略，以减少LD对HIV健康HIV健康的长期影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176812/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176812</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961418/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961418</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1436589>10.3389/fimmu.2025.1436589</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176812</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> yihui他</dc:creator><dc:creator>刘</dc:creator><dc:creator>Meixin Ren</dc:creator><dc:creator> Gaungqiang太阳</dc:creator><dc:creator>少女</dc:creator><dc:creator>Miaotian CAI</dc:creator><dc:creator>鲁·王（Rui Wang）</dc:creator><dc:creator> Lei Wang</dc:creator><dc:creator> Tong Zhang</dc:creator><dc:creator>杨张</dc:creator><dc:date>2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>脑损伤，内分泌干扰和与患有晚期HIV诊断男性发生性关系的HIV阳性男性的免疫失调</dc:title><dc:identifier>PMID：40176812</dc:identifier><dc:identifier> PMC：PMC11961418</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1436589</dc:identifier></item><item><title>黑色大豆（&lt;em>; ronynchosia nulubilis &lt;/em>;）和黑米（&lt;em>; oryza sativa &lt;/em>; L.）提取的黑大豆（&lt;em>; Rhynchosia nulubilis &lt;/em>;）提取的衰老诱导的肌肉下降。</title><link/> https://pubmed.ncbi.nlm.nih.gov/40176811/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>衰老导致骨骼肌的质量和功能下降，这种疾病称为肌肉减少症。先前据报道，与衰老相关的蛋白质降解，慢性炎症和线粒体代谢的恶化会影响老年人肌肉萎缩的加速。但是，仍然缺乏与年龄相关的肌肉损失的详细机制或实质性原因，但锻炼或饮食蛋白质摄入的锻炼是有效的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1554941。 doi：10.3389/fimmu.2025.1554941。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">衰老导致骨骼肌的质量和功能下降，这种疾病称为肌肉减少症。先前据报道，与衰老相关的蛋白质降解，慢性炎症和线粒体代谢的恶化会影响老年人肌肉萎缩的加速。但是，仍然缺乏与年龄相关的肌肉丧失的详细机制或实质性原因，但锻炼或饮食蛋白质摄入的锻炼被认为是减轻肌肉萎缩的有效方法。这项研究旨在研究黑色大豆（ <i>Rhynchosia nulubilis</i> ）和黑米（ <i>Oryza sativa</i> L.）混合物提取物（BBME）的调节作用，它们富含蛋白质和生物活性化合物，在12个月大的年龄小鼠和L6 myotubes中。 BBME以300和600 mg/kg/day（低剂量和高剂量）口服12周，并评估了其对全身葡萄糖稳态和骨骼肌代谢的影响。因此，在高剂量的肌肉减轻肌肉损失和明显改善葡萄糖代谢的情况下，BBME。 BBME还降低了老年骨骼肌的细胞衰老标记和增强的线粒体生物发生。另外，BBME通过促进L6肌管中的葡萄糖代谢来发挥胰岛素样活性。这些发现表明，通过调节线粒体活性和葡萄糖代谢，BBME作为功能性食品成分在减轻衰老引起的肌肉丧失方面的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176811/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176811</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961972/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961972</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1554941>10.3389/fimmu.2025.1554941</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176811</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Hyejeong公园</dc:creator><dc:creator>seungmin yu</dc:creator><dc:creator> Wooki Kim</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>黑色大豆（&lt;em>; ronynchosia nulubilis &lt;/em>;）和黑米（&lt;em>; oryza sativa &lt;/em>; L.）提取的黑大豆（&lt;em>; Rhynchosia nulubilis &lt;/em>;）提取的衰老诱导的肌肉下降。</dc:title><dc:identifier> PMID：40176811</dc:identifier><dc:identifier> PMC：PMC11961972</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1554941</dc:identifier></item><item><title> Circrnas：一种治疗乳腺癌的新型潜在策略</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176810/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>乳腺癌是全球最普遍的恶性肿瘤之一，其中三阴性乳腺癌（TNBC）是最具侵略性的亚型，缺乏有效的治疗选择。圆形RNA（CIRCRNA）是非编码的RNA，在包括乳腺癌在内的肿瘤发展中起着至关重要的作用。本文探讨了乳腺癌中CIRCRNA的研究进展，重点是四个主要领域：1）乳腺癌流行病学，分类和治疗； 2）结构，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1563655。 doi：10.3389/fimmu.2025.1563655。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">乳腺癌是全球最普遍的恶性肿瘤之一，其中三阴性乳腺癌（TNBC）是最具侵略性的亚型，缺乏有效的治疗选择。圆形RNA（CIRCRNA）是非编码的RNA，在包括乳腺癌在内的肿瘤发展中起着至关重要的作用。本文探讨了乳腺癌中CIRCRNA的研究进展，重点是四个主要领域：1）乳腺癌流行病学，分类和治疗； 2）CIRCRNA的结构，发现过程，特征，形成和功能； 3）在乳腺癌细胞和免疫微环境中，特别是在TNBC中，表达，机制，临床相关性和最新进展； 4）在卑诗省研究中使用circrnas的挑战和未来前景。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176810/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176810</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961433/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961433</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1563655>10.3389/fimmu.2025.1563655</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176810</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Pangzhou Chen</dc:creator><dc:creator>金胡伊张</dc:creator><dc:creator>歌曲Wu</dc:creator><dc:creator>张张</dc:creator><dc:creator>Wen Zhou</dc:creator><dc:creator> Ziyun Guan</dc:creator><dc:creator> Hailin Tang</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>Circrnas：一种治疗乳腺癌的新型潜在策略</dc:title><dc:identifier>PMID：40176810</dc:identifier><dc:identifier> PMC：PMC11961433</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1563655</dc:identifier></item><item><title>罕见的&lt;em>; cxcl8 &lt;/em>;基因变体是炎症性肠病的新可能原因还是诅咒因素？</title><link/> https://pubmed.ncbi.nlm.nih.gov/40176809/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>结论：这表明CXCL8 C.91T等位基因可能影响波兰患者的IBD表现和疾病的进程，这可能是未来研究和治疗方法的新目标。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1562618。 doi：10.3389/fimmu.2025.1562618。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：炎症性肠病的发病机理（IBD）涉及遗传，环境，免疫学和微生物因子；但是，目前尚不清楚。由<i>CXCL8</i>基因编码的促炎性白介素8（IL-8）在白细胞迁移中具有至关重要的趋化作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：本研究旨在研究IBD和两个<i>CXCL8</i>变体之间是否存在关联，即C.-251A>; t（RS4073）和C.91G>; t（RS188378669）和IL-8浓度。我们使用焦磷酸测序，竞争性等位基因特异性PCR和Sanger测序分析了353名波兰IBD患者和200名人群受试者的两种变体的分布。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：IBD患者（2.12％）的C.91T加工等位基因比对照组（0.25％）（ <i>p</i> = 0.0121）明显高得多，而C.-251T等位基因频率相似（54％vs. 51.5％， <i>P</i> = 0.4955）。与健康对照组相比，使用ELISA测量的血清IL-8浓度在C.91 GG基因型的IBD患者中较高（平均70.02 vs. 51.5 pg/ml， <i>P</i> &lt;0.01），均值C.91 GT患者（平均值为61.73 pg/mL）。此外，临床数据表明，与GG纯合IBD患者相比，C.91T变体的携带者更需要皮质类固醇和手术治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这表明<i>CXCL8</i> C.91T等位基因可能影响波兰患者的IBD表现和疾病的进程，这可能是未来研究和治疗方法的新目标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176809/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176809</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961448/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961448</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1562618>10.3389/fimmu.2025.1562618</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176809</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator>马辛·加布里尔（Marcin Gabryel）</dc:creator><dc:creator> Oliwia Zakerska-Banaszak</dc:creator><dc:creator>卡罗琳娜·拉兹克（Karolina Ladziak）</dc:creator><dc:creator> Katarzyna Anna Hubert</dc:creator><dc:creator> Alina Baturo</dc:creator><dc:creator>乔安娜·萨斯基斯卡 - 扎吉克</dc:creator><dc:creator>Magdalena Hryhorowicz</dc:creator><dc:creator> agnieszka dobrowolska</dc:creator><dc:creator> Marzena Skrzypczak-Zielinska</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>罕见的&lt;em>; cxcl8 &lt;/em>;基因变体是炎症性肠病的新可能原因还是诅咒因素？</dc:title><dc:identifier> PMID：40176809</dc:identifier><dc:identifier> PMC：PMC11961448</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1562618</dc:identifier></item><item><title>口咽癌诱导循环单核细胞表达像TAM样的促肿瘤表达曲线，可抑制T细胞增殖</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176808/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>结论：针对单核细胞早期过渡到促肿瘤TAMS，可以用于开发针对OPC的新疗法。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1539780。 doi：10.3389/fimmu.2025.1539780。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：从循环单核细胞募集的肿瘤相关巨噬细胞（TAM）驱动肿瘤生长并建立免疫抑制性肿瘤微环境（TME）。从静止单核细胞到TAM的过渡中的最初事件知之甚少。在这里，我们报告说，来自OPC条件培养基（CM）治疗的口咽癌（OPC）患者（OPC）患者（OPC）的单核细胞表达了TAMS特征的亲肿瘤介质的曲目。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：用单细胞RNASEQ分析的OPC细胞系CM刺激单核细胞。通过QPCR用单核细胞证实了选定基因的结果，并在OPC肿瘤与临床上正常组织中进行了分析。建立了含有对照单核细胞和T细胞的OPC球体，以流量分析和qPCR为特征的TAM表型，以及通过流量评估的T细胞增殖。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：OPC条件的培养基诱导了多个促肿瘤基因，包括<i>CXCL1，CXCL5，CXCL8，SPP1，IL1B，GPNMB</i>和<i>FABP5</i> 。患者单核细胞的基线水平高或刺激后的水平高于对照单核细胞。患者单核细胞的一部分具有高基线水平的<i>CXCL9/-10/-11</i>表达，可抵抗响应刺激的下调，这是TME更有利的潜在迹象。与临床正常组织相比，OPC肿瘤活检中的<i>CXCL9/-10/-11</i>表达与患者结局相关。从对照单核细胞中得出的球体TAM保持了肿瘤线调节培养基刺激的单核细胞的促肿瘤曲目。这些TAM抑制T细胞增殖。在分化为TAM中的COX-2或IL1信号的抑制部分阻止了T细胞增殖的抑制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：针对单核细胞早期过渡到促肿瘤TAMS，可以用于开发针对OPC的新疗法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176808/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176808</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961958/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961958</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1539780>10.3389/fimmu.2025.1539780</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176808</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Christopher J Papayannakos</dc:creator><dc:creator> Mohd Israr</dc:creator><dc:creator>詹姆斯·迪瓦蒂</dc:creator><dc:creator>真菌林</dc:creator><dc:creator>Arnon Arazi</dc:creator><dc:creator>道格拉斯·K弗兰克</dc:creator><dc:creator>开发P Kamdar</dc:creator><dc:creator> Lucio M Pereira</dc:creator><dc:creator> Nagashree Seetharamu</dc:creator><dc:creator> Bettie M Steinberg</dc:creator><dc:creator> Vincent R Bonagura</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>口咽癌诱导循环单核细胞表达像TAM样的促肿瘤表达曲线，可抑制T细胞增殖</dc:title><dc:identifier>PMID：40176808</dc:identifier><dc:identifier> PMC：PMC11961958</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1539780</dc:identifier></item><item><title>免疫病发生和临床实践的最新进展：掌握非结核分枝杆菌挑战的挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176807/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>非结核分枝杆菌（NTM）是广泛的环境病原体，可能导致疾病负担重大负担，尤其是在免疫功能低下的个体中，但在患有正常免疫系统的人中也会导致疾病负担。 NTM的全球发病率正在迅速增加，而分枝杆菌（MAC）是最常见的类型之一。 MAC的免疫发病发生涉及细菌与宿主免疫系统之间的复杂相互作用。 MAC在巨噬细胞中存活并复制... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月19日； 16：1554544。 doi：10.3389/fimmu.2025.1554544。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">非结核分枝杆菌（NTM）是广泛的环境病原体，可能导致疾病负担重大负担，尤其是在免疫功能低下的个体中，但在患有正常免疫系统的人中也会导致疾病负担。 NTM的全球发病率正在迅速增加，而分枝<i>杆菌</i>（MAC）是最常见的类型之一。 MAC的免疫发病发生涉及细菌与宿主免疫系统之间的复杂相互作用。 MAC通过防止吞噬体和溶酶体的融合而在巨噬细胞中生存和重复。分枝杆菌可以中和巨噬细胞通过自己的酶产生的活性氧和氮。此外，MAC调节细胞因子的产生，使其抑制或调节免疫反应。诊断MAC感染可能具有挑战性，由于MAC对不同地区对各种抗菌药物的耐药性的不可预测性，可用治疗的有效性可能受到限制。治疗MAC感染需要一种协作方法，涉及不同的医疗保健专业人员并确保患者合规性。这篇综述旨在阐明MAC感染治疗的复杂性，讨论MAC感染诊断的挑战，药理学考虑因素，例如药物治疗方案，药物监测，药物相互作用以及多学科医疗团队在实现患者最佳治疗方面的关键作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40176807/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176807</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961655/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961655</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1554544>10.3389/fimmu.2025.1554544</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40176807</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Wiwat Chancharoenthane</dc:creator><dc:creator> supitcha kamolratanakul</dc:creator><dc:creator> suwatchareeporn rotcheewaphan</dc:creator><dc:creator> Asada Leelahavanichkul</dc:creator><dc:creator> Marcus J Schultz</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>免疫病发生和临床实践的最新进展：掌握非结核分枝杆菌挑战的挑战</dc:title><dc:identifier>PMID：40176807</dc:identifier><dc:identifier> PMC：PMC11961655</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1554544</dc:identifier></item><item><title> SCD40和SCD40L作为风湿病的候选生物标志物：系统的综述和荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40176806/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250403141505＆v = 2.18.0.post9+e462414<description>持续寻找新型生物标志物，以增强风湿病患者（RDS）的诊断和监测。 We conducted a systematic review and meta-analysis to investigate the potential role of the soluble cluster of differentiation 40 (sCD40) and sCD40 ligand (sCD40L), involved in humoral and cellular immune response, as candidate biomarkers of RDs. We searched PubMed, Web of Science, and Scopus from inception to 30 June 2024 for studies investigating circulating sCD40 and... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 19;16:1479904. doi: 10.3389/fimmu.2025.1479904.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> There is an ongoing search for novel biomarkers to enhance diagnosing and monitoring patients with rheumatic diseases (RDs). We conducted a systematic review and meta-analysis to investigate the potential role of the soluble cluster of differentiation 40 (sCD40) and sCD40 ligand (sCD40L), involved in humoral and cellular immune response, as candidate biomarkers of RDs. We searched PubMed, Web of Science, and Scopus from inception to 30 June 2024 for studies investigating circulating sCD40 and sCD40L concentrations in RD patients and healthy controls. We assessed the risk of bias using the Joanna Briggs Institute Critical Appraisal Checklist for analytical studies and the certainty of evidence using the Grades of Recommendation, Assessment, Development and Evaluation Working Group system. Compared to controls, RD patients had significantly higher sCD40L (31 studies; standard mean difference, SMD=0.87, 95% CI 0.60 to 1.13, p&lt;0.001; low certainty of evidence) and sCD40 (five studies; SMD=1.32, 95% CI 0.45 to 2.18, p=0.003; very low certainty of evidence) concentrations. In meta-regression and subgroup analysis, the effect size of the between-group differences in sCD40L was significantly associated with sample size, mean RD duration, specific RD, biological matrix assessed, and analytical method used. By contrast, there were no associations with age, sex, C-reactive protein, erythrocyte sedimentation rate, use of disease-modifying antirheumatic drugs or glucocorticoids, or geographical location. There were no significant differences in sCD40L concentrations between RD patients with and without active disease (eight studies; SMD=0.12, 95% CI -0.09 to 0.33, p=0.26; very low certainty). By contrast, sCD40 concentrations were significantly higher in RD patients with active disease (three studies; SMD=0.36, 95% CI 0.08 to 0.84, p=0.013; very low certainty). Our systematic review and meta-analysis suggests the potential role of sCD40 and sCD40L as candidate biomarkers to detect the presence of RDs (sCD40 and sCD40L) and monitor disease activity (sCD40). Large, appropriately designed prospective studies in a wide range of RDs are warranted to investigate whether measuring sCD40 and sCD40L can significantly improve the performance of currently available diagnostic criteria and serological biomarkers. (PROSPERO registration number: CRD42024577430). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024577430, identifier PROSPERO CRD42024577430.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40176806/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176806</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11962221/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11962221</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1479904>10.3389/fimmu.2025.1479904</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40176806</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Angelo Zinellu</dc:creator><dc:creator> Arduino A Mangoni</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>sCD40 and sCD40L as candidate biomarkers of rheumatic diseases: a systematic review and meta-analysis with meta-regression</dc:title><dc:identifier> pmid:40176806</dc:identifier><dc:identifier> pmc:PMC11962221</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1479904</dc:identifier></item><item><title> Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE&lt;sub>;2&lt;/sub>; signaling pathway in mice</title><link/> https://pubmed.ncbi.nlm.nih.gov/40176805/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250403141505&amp;v=2.18.0.post9+e462414<description> INTRODUCTION: Lung cancer is characterized by a poor prognosis and is a significant comorbidity of chronic obstructive pulmonary disease (COPD). Therefore, effective chemopreventive agents are warranted. We evaluated the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on the prevention of lung-carcinoma development using an intermittent smoking-induced lung-carcinoma mouse model. Additionally, we explored COX-2&#39;s role in lipid metabolism. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 19;16:1557790. doi: 10.3389/fimmu.2025.1557790.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Lung cancer is characterized by a poor prognosis and is a significant comorbidity of chronic obstructive pulmonary disease (COPD). Therefore, effective chemopreventive agents are warranted. We evaluated the effects of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on the prevention of lung-carcinoma development using an intermittent smoking-induced lung-carcinoma mouse model. Additionally, we explored COX-2&#39;s role in lipid metabolism. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Male A/J mice were exposed to sham air or mainstream cigarette smoke for 20 weeks. Vehicle or celecoxib was administered via intragastric feeding once daily. Lung tissues were analyzed for tumor nodules and emphysema; the bronchoalveolar lavage fluid was collected for cell counting. COX-2 expression was measured using real-time polymerase chain reaction and western blotting; lipidomic analysis was conducted using liquid chromatography-tandem mass spectrometry. Cell proliferation and colony-forming assays were performed on LA-4 cells to assess the effects of prostaglandins and COX-2 inhibitors. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Intermittent smoking exposure increased lung adenomas, adenocarcinomas, and COX-2 expression. Lung adenomas were characterized by abundant COX-2-positive cells. Celecoxib reduced intermittent smoking-induced inflammation, emphysema, and cell counts in the bronchoalveolar lavage fluid and decreased the incidence of lung adenocarcinomas, whereas the total number of observed lung tumors was unchanged. Celecoxib markedly suppressed single-smoke-induced prostaglandin E2 (PGE <sub>2</sub> ) production in the airway. PGE <sub>2</sub> increased LA-4 cell viability via the EP4 receptor and promoted colony formation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DISCUSSION: Celecoxib effectively inhibited lung-carcinoma development, inflammation, and emphysema, demonstrating the potential for chemoprevention in smokers and patients with COPD. Further studies on EP4 inhibitors for the prevention of emphysema and lung cancer are warranted.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40176805/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176805</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961424/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961424</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1557790>10.3389/fimmu.2025.1557790</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40176805</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Kaori Sakurai</dc:creator><dc:creator> Shotaro Chubachi</dc:creator><dc:creator> Jun Miyata</dc:creator><dc:creator> Junko Hamamoto</dc:creator><dc:creator> Tatsuro Naganuma</dc:creator><dc:creator> Takashi Shimada</dc:creator><dc:creator> Shiro Otake</dc:creator><dc:creator> Shingo Nakayama</dc:creator><dc:creator> Hidehiro Irie</dc:creator><dc:creator> Akihiro Tsutsumi</dc:creator><dc:creator> Naofumi Kameyama</dc:creator><dc:creator> Ahmed E Hegab</dc:creator><dc:creator> Masayuki Shimoda</dc:creator><dc:creator> Hideki Terai</dc:creator><dc:creator> Hiroyuki Yasuda</dc:creator><dc:creator> Yae Kanai</dc:creator><dc:creator> Makoto Arita</dc:creator><dc:creator> Koichi Fukunaga</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE&lt;sub>;2&lt;/sub>; signaling pathway in mice</dc:title><dc:identifier> pmid:40176805</dc:identifier><dc:identifier> pmc:PMC11961424</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1557790</dc:identifier></item><item><title> Iron and energy metabolic interactions in Treg-mediated immune regulation</title><link/> https://pubmed.ncbi.nlm.nih.gov/40176804/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250403141505&amp;v=2.18.0.post9+e462414<description> Immunometabolism, the study of how metabolic processes influence immune cell function, has emerged as a critical field in understanding the regulation of immune tolerance and the pathological mechanisms underlying autoimmune diseases. Intracellular metabolic pathways not only provide the necessary energy for immune cell survival and activity but also shape the differentiation, phenotype, proliferation, and effector functions of immune cells. This is particularly evident in CD4+ Foxp3+ regulatory... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 19;16:1554028. doi: 10.3389/fimmu.2025.1554028.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Immunometabolism, the study of how metabolic processes influence immune cell function, has emerged as a critical field in understanding the regulation of immune tolerance and the pathological mechanisms underlying autoimmune diseases. Intracellular metabolic pathways not only provide the necessary energy for immune cell survival and activity but also shape the differentiation, phenotype, proliferation, and effector functions of immune cells. This is particularly evident in CD4+ Foxp3+ regulatory T cells (Treg), which are pivotal for maintaining immune homeostasis and preventing autoimmune reactions. Strong experimental evidence highlights the profound impact of metabolism on Treg. Their anti-inflammatory function and ability to suppress excessive immune responses depend on the integration of metabolic cues with their transcriptional and signaling networks. Iron metabolism and mitochondrial dynamics are among the key factors influencing Treg function. This review focuses on how iron and mitochondrial metabolism shape Treg biology and function.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40176804/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176804</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961939/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961939</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1554028>10.3389/fimmu.2025.1554028</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40176804</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Frédérique Savagner</dc:creator><dc:creator> Thomas Farge</dc:creator><dc:creator> Zoubida Karim</dc:creator><dc:creator> Meryem Aloulou</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>Iron and energy metabolic interactions in Treg-mediated immune regulation</dc:title><dc:identifier> pmid:40176804</dc:identifier><dc:identifier> pmc:PMC11961939</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1554028</dc:identifier></item><item><title> Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome</title><link/> https://pubmed.ncbi.nlm.nih.gov/40176803/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250403141505&amp;v=2.18.0.post9+e462414<description> Immune checkpoint inhibitors (ICIs) have revolutionized hepatocellular carcinoma (HCC) treatment, while immune-related adverse events (IRAEs) pose significant challenges. We report a 60-year-old male with unresectable HCC who developed Guillain-Barré syndrome (GBS), a rare but severe neurologic complication, after three cycles of sintilimab plus bevacizumab biosimilar and conventional transarterial chemoembolization (c-TACE). The patient presented with progressive ascending weakness, reaching... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 19;16:1546886. doi: 10.3389/fimmu.2025.1546886.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Immune checkpoint inhibitors (ICIs) have revolutionized hepatocellular carcinoma (HCC) treatment, while immune-related adverse events (IRAEs) pose significant challenges. We report a 60-year-old male with unresectable HCC who developed Guillain-Barré syndrome (GBS), a rare but severe neurologic complication, after three cycles of sintilimab plus bevacizumab biosimilar and conventional transarterial chemoembolization (c-TACE). The patient presented with progressive ascending weakness, reaching symmetric quadriparesis with proximal muscle strength of 2/5 in upper limbs and 1/5 in lower limbs. Following sintilimab discontinuation, treatment with intravenous immunoglobulin (2 g/kg) and oral prednisone (30 mg/day) achieved complete neurological recovery within one month. Given the patient&#39;s favorable initial tumor response and strong request, immunotherapy was cautiously reinstated using tislelizumab after thorough clinical evaluation. Following four cycles of treatment, significant tumor response enabled successful conversion surgery with major pathological response (necrosis rate >;70%). With 26-month survival and no evidence of recurrence, this case demonstrates the potential feasibility of ICI rechallenge with an alternative PD-1 inhibitor following sintilimab-induced GBS. Our experience suggests that ICI-related neurological adverse events may be drug-specific rather than class-specific, potentially providing valuable treatment options for patients showing favorable tumor response despite experiencing severe IRAEs, though larger studies are needed for validation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40176803/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">40176803</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11961408/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250403141505&v=2.18.0.post9+e462414">PMC11961408</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1546886>10.3389/fimmu.2025.1546886</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40176803</guid><pubDate> Thu, 03 Apr 2025 06:00:00 -0400</pubDate><dc:creator>林耶</dc:creator><dc:creator>Wan Rong Yue</dc:creator><dc:creator> Hao Shi</dc:creator><dc:creator> Jian Ren Li</dc:creator><dc:creator> Yu Ya Qun</dc:creator><dc:date> 2025-04-03</dc:date><dc:source>免疫学领域</dc:source><dc:title>Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome</dc:title><dc:identifier> pmid:40176803</dc:identifier><dc:identifier> pmc:PMC11961408</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1546886</dc:identifier></item></channel></rss>